^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK-KIF5B fusion

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, KIF5B, Kinesin Family Member 5B, Conventional Kinesin Heavy Chain, Ubiquitous Kinesin Heavy Chain, Kinesin-1 Heavy Chain, KNS1, UKHC, KNS, Epididymis Secretory Protein Li 61, Kinesin 1 (110-120kD), Kinesin Heavy Chain, HEL-S-61, KINH
    Entrez ID:
    238; 3799
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Routine next generation sequencing testing on lung adenocarcinoma pap-stained (OH-fixed) cytological samples (ECP 2023)
    7 studies were invalid for both ADN&RNA,in 5 for DNA, one for ARN and in two cases without CNV detection.T% median was 90%(mean 75.4%). Among patients with invalid results 10 were rebiopsied. Thirty two patients have no genomic aberrations (24.4%).Co-ocurring molecular alterations-rate was 47,5%.Molecular alterations in KRAS and EGFR genes were the most frequent identified in 37(33%) and 22(16%) cases respectively.
    Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • ALK fusion • KIF5B-RET fusion • ALK-KIF5B fusion
    |
    Oncomine Focus Assay